Navigation Links
Dune Medical Devices Hosts Symposium Featuring MarginProbe® System at European Breast Cancer Conference
Date:3/22/2012

VIENNA, March 22, 2012 /PRNewswire/ -- Dune Medical Devices, the manufacturer of the MarginProbe® System, held a satellite symposium featuring discussions with experts in the field of breast cancer regarding the treatment of women with early stage breast cancer and the importance of margin assessment in breast conserving surgery. The panel conducted a thorough review of clinical experience with the MarginProbe System, designed to improve a surgeon's ability to identify the presence of cancer on the margin of excised tissue during lumpectomy.  The event was held at The European Breast Cancer Conference (EBCC) in Vienna, Austria, March 21, 2012.

Symposium moderator, Alberto Costa, M.D., Editor-in-chief of the journal The Breast, and the author of more than 250 scientific publications, said, "Current data shows that cancer is still present at the margin in over 20 percent of breast cancer patients after surgery, therefore requiring an additional operation.  We have long awaited a technology that could help improve our ability to remove all of a patient's cancer in one surgery.  The MarginProbe System represents a unique breakthrough for surgeons everywhere.  I am excited about the opportunity to be directly involved in the introduction of this product to surgeons in Europe."

The symposium, titled "Intraoperative Margin Assessment: MarginProbe®, Real-time Identification of Positive Margins for the Breast Surgeon," included results from multiple studies in over 1,000 patients throughout Europe, the United States and Israel from distinguished researchers. 

Mark Gittleman, M.D., a principal investigator in the pivotal U.S. trial of the MarginProbe System, described the significant increase in the ability of the surgeon to achieve a clear resection margin of the tumor in the breast during the first surgical intervention and to thus reduce the need for repeat surgeries. 

Marc Thill, M.D., of the Department of Obstetrics and Gynecology, University Hospital of Schleswig-Holstein, Lubeck, Germany presented results in patients with early stage, in situ lesions in whom clear margin status is a frequent surgical dilemma.

In addition, researchers from the University of California at San Francisco presented cost-effectiveness research that shows opportunity for significant cost-reduction associated with intraoperative use of MarginProbe System during breast conserving surgery.

Dan Levangie, CEO, Dune Medical Devices, said, "We are excited to have the opportunity to convene such a prestigious group of industry thought leaders to discuss the potential benefits the MarginProbe System can provide to patients living with breast cancer. We are committed to supporting and conducting continued research in this field and expanding the availability of this early detection device to patients throughout Europe to improve quality of life and successful surgical outcomes."

About the MarginProbe System

The MarginProbe System enables real time detection of cancer at or near the surface of excised tissue specimens during surgery for breast cancer.  Used as an addition to standard breast conserving surgery techniques, such as lumpectomy, the simple and immediate assessment performed with the MarginProbe System reduces the number of re-excisions needed.

The MarginProbe System is commercially available in Europe and is an investigational device in the U.S.

About Dune Medical Devices

Dune Medical Devices was founded in 2002 by Dr. Dan Hashimshony to realize the extraordinary medical potential of its proprietary tissue characterization technology.  Offering surgeons and radiologists the real time ability to identify cancerous tissues and react immediately, this technology holds the promise for a broad range of surgical and diagnostic applications.  The MarginProbe System is Dune's first commercial product and is commercially available in Europe.  The MarginProbe device is an investigational device in the U.S.

Dune Medical Devices is a privately held company financed by Apax Partners since 2004.  It has offices in the U.S., Israel, Germany and Switzerland.  For more information, please visit www.dunemedical.com   

Contact:
Michael Graffeo
Dune Medical Devices
Michael.graffeo@dunemedical.com
(508) 620-2782


'/>"/>
SOURCE Dune Medical Devices
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivans Advanced Medical Technologies Research Tracks Opportunities in Markets Influenced by Dynamic Care Pathways
2. OptiScan Biomedical Presents Study Results Demonstrating OptiScanners Excellent Glucose Monitoring Accuracy in Critically Ill ICU Patients
3. Consumer Reports Poll: Americans Overwhelmingly Support Strong Medical Device Safety Oversight
4. The Outlook for Medical Devices in Central Asia
5. The Outlook for Medical Devices in South East Asia
6. Pricing and Reimbursement Strategies for Medical Devices
7. Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results
8. Opto-Acoustic Transducers Remove Blockages. ICAP Patent Brokerage Announces for Auction Important Patents for Medical Techniques and Devices That Perform Blockage Removal Using Lasers, Ultrasonics, and Fiber Optics
9. Siemens and ASCP Award Over 100 Scholarships to Medical Laboratory Students in 2012
10. Weill Cornell Medical College Selects Ingenuity® Variant Analysis™ and Ingenuity® iReport™ for Sequencing Core Facility
11. arGEN-X Appoints Alain Thibault as Chief Medical Officer and Koos Rasser as IP Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... , March 30, 2017  Lannett Company, Inc. (NYSE: ... voluntarily made a $25 million payment against its existing ... payment, combined with the $75 million payment we made ... $5.5 million in annualized cash interest expense, at current ... of Lannett.  "Our business is solid and we continue ...
(Date:3/30/2017)... Mar 30, 2017 Research and Markets ... Dialysis Market Size & Forecast, By Type (Hemodialysis, Peritoneal Dialysis), ... Trend Analysis From 2014 To 2025" report to their ... ... to reach USD 108.5 billion by 2025. ...
(Date:3/29/2017)... , March 29, 2017  Bodycad announced ... Drug Administration (FDA) 510(k) clearance for its Bodycad ... this truly personalized orthopaedic restoration. Bodycad is the ... a joint reconstruction implant system. ... optimize personalized restoration of the patient,s unique anatomical ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... During the last week of March, Chad Kawa, ... eligible individuals in the local community. , Colon cancer is the second leading ... colon cancer while it is small, confined and easier to treat. If you are ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, up to 36% ... other types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic brain tumors ... finding more effective treatment options, the San Diego Gamma Knife Center offers ...
(Date:3/29/2017)... Atlanta, Georgia (PRWEB) , ... March 29, 2017 , ... ... Theresa Therilus, founder of Pet Protect Law that assists dog owners in ... will assist new owners in taking the natural next step to protect their new ...
(Date:3/29/2017)... ... ... CHARM CITY RUN WELCOMES MERCY MEDICAL CENTER AS , BALTIMORE WOMEN’S CLASSIC ... as the official title sponsor of the Baltimore Women’s Classic, the largest all women’s ... will walk or run the course around the Baltimore Inner Harbor. Mercy has been ...
(Date:3/29/2017)... ... , ... Sublime Naturals and its founder, Kathy Heshelow, are big fans of ... used for thousands of years. , "The West has caught on, and has discovered ... to Use it For Your Wellness. Overcome Inflammation, Enemy of the Body. " ...
Breaking Medicine News(10 mins):